Cadrenal Therapeutics announced that the United States FDA has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, right ventricular assist device, collectively known as ventricular assist devices, biventricular assist device, and total artificial heart.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
Questions or Comments about the article? Write to editor@tipranks.com